Phylloquinone
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Phylloquinone: From Vitamin K Deficiency to Renal Tubular Acidosis
One-Sentence Summary
Phylloquinone (Vitamin K1) is a well-established agent for vitamin K deficiency and related coagulopathy, though this Evidence Pack contains no confirmed original-indication or mechanism-of-action record (flagged as data gaps DG001/DG002). The TxGNN model predicts a possible signal for Renal Tubular Acidosis, but this is currently supported by 0 clinical trials and 0 publications — a model-only prediction (Evidence Level L5).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in Evidence Pack (no licenses on record; MOA flagged as data gap DG002) |
| Predicted New Indication | Renal Tubular Acidosis |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for this candidate is not available in the Evidence Pack (data gap DG002). Based on general pharmacological knowledge, Phylloquinone acts via γ-carboxylation of glutamate residues, a post-translational modification required for clotting factors II/VII/IX/X, osteocalcin, and matrix Gla protein (MGP).
The Evidence Pack’s own mechanistic assessment for this top-ranked prediction is explicit that no plausible biological link exists: renal tubular acidosis arises from dysfunction of renal acid–base transport proteins (e.g. SLC4A1, ATP6V0A4), a pathway with no known intersection with the vitamin K–dependent carboxylation system. The high TxGNN score therefore reflects a statistical/model signal rather than a mechanistically grounded hypothesis, and the same “no known link” conclusion applies to all nine other ranked predictions in this pack (hypophosphatemic rickets, Pendred syndrome, and several rare monogenic disorders).
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
Phylloquinone has no ARTG entries on record and is currently not marketed in Australia (0 licenses).
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information. (Key warnings, contraindications, and drug interaction data are not available in this Evidence Pack — DG001, blocking.)
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate has zero clinical trial or literature support, no confirmed MOA, and the model’s own rationale explicitly finds no mechanistic connection between vitamin K pathways and renal tubular acidosis — the score is a pure L5 model prediction. A blocking safety data gap (DG001: TFDA/TGA product information and contraindications) also prevents entry into S1 safety screening.
To proceed, the following is needed:
- TGA/TFDA-approved Product Information — warnings, contraindications (DG001, blocking)
- Confirmed mechanism of action via DrugBank (DG002)
- Confirmation of the drug’s original approved indication(s)
- Independent literature or mechanistic search specifically probing vitamin K pathways in renal tubular acidosis before any further evaluation stage
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.